Stories about Genetik

LTS Lohmann Therapie-Systeme AG

LTS wins funding from BARDA’s Patch Forward Prize Competition for two partnerships

Helmholtz Zentrum München

SCP-Nano: A New Technology to Visualize Nanocarriers in Cells and Tissues

BIAL SA

BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 - a Novel Therapy for GBA1 Parkinson's Disease

Porto, Portugal (ots/PRNewswire) - BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE Phase 2 study. BIA 28-6156 is a first-in-class, small molecule for once-daily oral ...

RHEACELL GmbH und Co. KG

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Helmholtz Zentrum München

Maria-Elena Torres-Padilla Honored With the Leibniz Prize 2025

Technische Universität München

Complex pancreatic tumor organoids as foundation for new treatment strategies

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Foundation for new cancer treatment strategies Organoids represent the complex cell landscape of pancreatic cancer - Tumors are composed of cancer cells with a variety of different characteristics. - This contributes significantly to the complexity of pancreatic cancer and makes the disease difficult to treat. - For the ...

Helmholtz Zentrum München

Inceptor Regulates Insulin Homeostasis: A New Approach for Diabetes Therapies

Technische Universität München

New method for designing artificial proteins

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Designing large new proteins with AI New method for designing artificial proteins - Efficient design of new proteins with desired properties - Size of newly designed proteins is approaching that of antibodies - Predicted protein structures successfully validated in experiments Protein design aims to create customized antibodies for therapies, biosensors for diagnostics, or ...

RHEACELL GmbH und Co. KG

RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU

Scantox A/S

Scantox Group acquires Gentronix, a world leader in genetic toxicology

Ejby, Denmark (ots/PRNewswire) - Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization ("CRO"). Gentronix, now integrated into Scantox Group, is well recognized for its high-quality genetic toxicology services and strong scientific engagement, with ...

Technische Universität München

What gave the first molecules their stability?

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE New insights into the origins of life What gave the first molecules their stability? • Until now, it was unclear how complex molecules could survive in the primordial soup• Unstable RNA molecules are stabilized by double strands • RNAs may be able to form their own complementary strand The origins of life remain a major mystery. How were complex molecules able to form and ...

Helmholtz Zentrum München

New Study: Father's Diet Before Conception Influences Children's Health

Helmholtz Zentrum München

Press Release: Restless Legs Syndrome: Genetic Discoveries Advance Treatment and Risk Prediction

Researchers at Helmholtz Munich and the Technical University of Munich (TUM) together with international collaborators have conducted the largest genetic investigation of the restless legs syndrome to date. Their findings, ...

STADA Arzneimittel AG

Press release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK

Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...

Medison Pharma; Alnylam Pharmaceuticals

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

Zug, Switzerland (ots/PRNewswire) - - The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance - Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient ...

Helmholtz Zentrum München

Advanced Brain Science Without Coding Expertise

Bosch Healthcare Solutions GmbH

Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform

Darmstadt, Gerlingen, and Waiblingen, Germany (ots) - Plans to use innovative Bosch BioMEMS technology in PCR tests for multiresistant bacteria - Bosch and R-Biopharm are jointly investing 150 million euros in the development of new PCR tests and in marketing. - PCR test for multiresistant gram-negative (MRGN) ...

Helmholtz Zentrum München

Asthma in Children: Researchers Envision Novel Drug to Reduce the Risk of the Disease

Asthma in Children: Researchers Envision Novel Drug to Reduce the Risk of the Disease Scientists have reached a milestone in the research of childhood asthma. For the first time, they have clarified how a certain genetic defect in children initially leads to frequent infections and later to asthma. The study, published in the American Journal of Respiratory and ...

Technische Universität München

Boron deficiency: oilseed rape reacts as with infection and pest infestation | Genetic mechanisms uncovered

TECHNICAL UNIVERSITY OF MUNICH PRESS RELEASE Genetic mechanisms uncovered Boron deficiency: oilseed rape reacts as with infection and pest infestation - Oilseed rape reacts to boron deficiency during flowering in a similar way as to pests and infections - Boron deficiency could become an increasing problem due to ...

Bosch Healthcare Solutions GmbH

Bosch and Randox: Strategic partnership brings highly multiplexing PCR to the point of care / BioMEMS technology enables fully automated, simultaneous testing for hundreds of genetic characteristics in just a few minutes

Waiblingen (ots) - - Bosch and Randox Laboratories Ltd. enter partnership for Vivalytic analysis platform to jointly invest around 150 million euros. - First test to feature novel BioMEMS technology will be a highly multiplexing sepsis IVD grade test. Bosch has agreed on a strategic partnership with Randox ...

Helmholtz Zentrum München

Scientists Reveal Adipocyte's Metabolic Role and Identify Treatment Targets

FDX Fluid Dynamix GmbH

4

FDX Fluid Dynamix and Fraunhofer IPK to Collaborate with Lonza on Novel Nanoparticle Formulation Technology Platform FDmiX

RHEACELL GmbH und Co. KG

Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘

Helmholtz Zentrum München

Rising Focus on 'Inceptor' as a Type 2 Diabetes Therapeutic Target